titoli, abstracts, parole chiave >>>
Discovery of potent pteridine reductase inhibitors to guide antiparasite drug development

Cavazzuti, Antonio and Paglietti, Giuseppe and Hunter, William N. and Gamarro, Francisco and Piras, Sandra and Loriga, Mario and Alleca, Sergio and Corona, Paola and McLuskey, Karen and Tulloch, Lindsay and Gibellini, Federica and Ferrari, Stefania and Costi, Maria Paola (2008) Discovery of potent pteridine reductase inhibitors to guide antiparasite drug development. Proceedings of The National Academy of Sciences, Vol. 105 (5), p. 1448-1453. eISSN 1091-6490. Article.

[img]
Preview
Full text disponibile come PDF Richiede visualizzatore di PDF come GSview, Xpdf o Adobe Acrobat Reader
671Kb

DOI: 10.1073/pnas.0704384105

Abstract

Pteridine reductase (PTR1) is essential for salvage of pterins by parasitic trypanosomatids and is a target for the development of improved therapies. To identify inhibitors of Leishmania major and Trypanosoma cruzi PTR1, we combined a rapid-screening strategy using a folate-based library with structure-based design. Assays were carried out against folate-dependent enzymes including PTR1, dihydrofolate reductase (DHFR), and thymidylate synthase. Affinity profiling determined selectivity and specificity of a series of quinoxaline and 2,4-diaminopteridine derivatives, and nine compounds showed greater activity against parasite enzymes compared with human enzymes. Compound 6a displayed a Ki of 100 nM toward LmPTR1, and the crystal structure of the LmPTR1:NADPH:6a ternary complex revealed a substrate-like binding mode distinct from that previously observed for similar compounds. A second round of design, synthesis, and assay produced a compound (6b) with a significantly improved Ki (37 nM) against LmPTR1, and the structure of this complex was also determined. Biological evaluation of selected inhibitors was performed against the extracellular forms of T. cruzi and L. major, both wild-type and overexpressing PTR1 lines, as a model for PTR1-driven antifolate drug resistance and the intracellular form of T. cruzi. An additive profile was observed when PTR1 inhibitors were used in combination with known DHFR inhibitors, and a reduction in toxicity of treatment was observed with respect to administration of a DHFR inhibitor alone. The successful combination of antifolates targeting two enzymes indicates high potential for such an approach in the development of previously undescribed antiparasitic drugs.

Item Type:Article
ID Code:1123
Status:Published
Refereed:Yes
Uncontrolled Keywords:Antitrypanosomatid agents, antifolates, drug discovery
Subjects:Area 03 - Scienze chimiche > CHIM/08 Chimica farmaceutica
Divisions:001 Università di Sassari > 01 Dipartimenti > Farmaco, chimico, tossicologico
Publisher:The National Academy of Sciences of the USA
eISSN:1091-6490
Publisher Policy:Depositato per gentile concessione dell'Editore. È vietato duplicare e postare il PDF. E' consentito l'uso a solo scopo di studio e di ricerca.
Deposited On:18 Aug 2009 10:04

I documenti depositati in UnissResearch sono protetti dalle leggi che regolano il diritto d'autore

Repository Staff Only: item control page